CN109963566A - 用低剂量硫鸟嘌呤进行体内化学选择 - Google Patents

用低剂量硫鸟嘌呤进行体内化学选择 Download PDF

Info

Publication number
CN109963566A
CN109963566A CN201780071180.4A CN201780071180A CN109963566A CN 109963566 A CN109963566 A CN 109963566A CN 201780071180 A CN201780071180 A CN 201780071180A CN 109963566 A CN109963566 A CN 109963566A
Authority
CN
China
Prior art keywords
weeks
days
amount
administered
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780071180.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·S·巴特利特
L·R·布雷顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring Gene Therapy Inc
Original Assignee
Calimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calimmune Inc filed Critical Calimmune Inc
Publication of CN109963566A publication Critical patent/CN109963566A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201780071180.4A 2016-11-18 2017-11-17 用低剂量硫鸟嘌呤进行体内化学选择 Pending CN109963566A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423794P 2016-11-18 2016-11-18
US62/423,794 2016-11-18
PCT/US2017/062127 WO2018094126A1 (en) 2016-11-18 2017-11-17 In vivo chemoselection with low dose thioguanine

Publications (1)

Publication Number Publication Date
CN109963566A true CN109963566A (zh) 2019-07-02

Family

ID=60915599

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780071180.4A Pending CN109963566A (zh) 2016-11-18 2017-11-17 用低剂量硫鸟嘌呤进行体内化学选择

Country Status (8)

Country Link
US (2) US20180140606A1 (enExample)
EP (1) EP3541392A1 (enExample)
JP (2) JP2019535737A (enExample)
KR (1) KR20190086497A (enExample)
CN (1) CN109963566A (enExample)
AU (1) AU2017363154A1 (enExample)
CA (1) CA3041531A1 (enExample)
WO (1) WO2018094126A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4190339B1 (en) * 2017-07-18 2025-07-02 CSL Behring Gene Therapy, Inc. A modulatable switch for selection of donor modified cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145723A1 (en) * 2011-04-20 2012-10-26 The Regents Of The University Of California Method for combined conditioning and chemoselection in a single cycle

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145723A1 (en) * 2011-04-20 2012-10-26 The Regents Of The University Of California Method for combined conditioning and chemoselection in a single cycle

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KATRIN HACKE等: "Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow", 《EXPERIMENTAL HEMATOLOGY》 *

Also Published As

Publication number Publication date
WO2018094126A1 (en) 2018-05-24
KR20190086497A (ko) 2019-07-22
AU2017363154A9 (en) 2019-07-11
JP2019535737A (ja) 2019-12-12
AU2017363154A1 (en) 2019-05-16
EP3541392A1 (en) 2019-09-25
JP2023025149A (ja) 2023-02-21
US20180140606A1 (en) 2018-05-24
US20190269687A1 (en) 2019-09-05
CA3041531A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
Rosemeyer The chemodiversity of purine as a constituent of natural products
Allison Mechanisms of action of mycophenolate mofetil
TWI615143B (zh) 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
EP2531194B1 (en) Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
TWI583385B (zh) 使用ｔｏｒ之激酶抑制劑之癌症治療
TWI674897B (zh) 藉二氫吡并吡化合物組合療法的癌症治療方法
Krungkrai et al. Insights into the pyrimidine biosynthetic pathway of human malaria parasite Plasmodium falciparum as chemotherapeutic target
JP6382948B2 (ja) 癌を治療するためのｔｏｒキナーゼ阻害剤及びシチジン類似体を含む組合せ療法
CN107921032A (zh) 用于治疗神经学疾病或病症的vmat2抑制剂
Varga et al. Intracellular metabolism of nucleoside/nucleotide analogues: a bottleneck to reach active drugs on HIV reverse transcriptase
Parker et al. Purine metabolism in Mycobacterium tuberculosis as a target for drug development
Kukhanova Anti-HIV nucleoside drugs: A retrospective view into the future
el Kouni Adenosine metabolism in Toxoplasma gondii: potential targets for chemotherapy
TWI233359B (en) Pharmaceutical composition for treating neoplasm
JP2025061603A (ja) 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用
JP2023025149A (ja) 低用量チオグアニンによるインビボ化学選択
Morris, Jr et al. Inhibitors of the enzyme purine nucleoside phosphorylase
HK40003311A (en) In vivo chemoselection with low dose thioguanine
Elion Historical background of 6-mercaptopurine
Dagen et al. Inhibitors of purine and pyrimidine pathways
Lamanna et al. Purine analogs in leukemia
Gao et al. Synthesis of mizoribine prodrugs and their in vivo evaluation as immunosuppressive agents
Curbo et al. Nelarabine-A New Purine Analog in the Treatment of Hematologic Malignancies
WO2022181514A1 (ja) 慢性骨髄性白血病幹細胞阻害剤
Curbo et al. 9-β-D-Arabinofuranosylguanine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003311

Country of ref document: HK

CB02 Change of applicant information

Address after: California, USA

Applicant after: CSL Beilin gene therapy Co.,Ltd.

Address before: Arizona, USA

Applicant before: CALIMMUNE Inc.

CB02 Change of applicant information
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190702

WD01 Invention patent application deemed withdrawn after publication